XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 27.4% in January

XOMA Royalty Corporation (NASDAQ:XOMA) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,051,282 shares, an increase of 27.4% from the January 15th total of 824,924 shares. Based on an average daily volume of 783,079 shares, the days-to-cover ratio is presently 1.3 days. Approximately 9.1% of the shares of the stock are short sold. Approximately 9.1% of the shares of the stock are short sold. Based on an average daily volume of 783,079 shares, the days-to-cover ratio is presently 1.3 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. UBS Group set a $76.00 target price on shares of XOMA Royalty in a research note on Tuesday, December 9th. Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a report on Friday, December 12th. Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Leerink Partners cut their price target on XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.60.

XOMA Royalty Trading Up 1.9%

NASDAQ XOMA opened at $24.47 on Wednesday. The stock has a 50-day simple moving average of $26.16 and a 200 day simple moving average of $31.14. The company has a market capitalization of $302.94 million, a PE ratio of 33.07 and a beta of 0.86. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92.

Insider Transactions at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes bought 100,000 shares of the stock in a transaction dated Thursday, December 4th. The stock was bought at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the purchase, the chief executive officer owned 102,000 shares in the company, valued at $2,555,100. This represents a 5,000.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 756 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in XOMA Royalty during the 4th quarter worth $27,000. Dimensional Fund Advisors LP lifted its holdings in XOMA Royalty by 4.5% during the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after acquiring an additional 1,269 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.